New eye bulging treatment tested against standard care
NCT ID NCT07265258
Summary
This study aims to see if a new drug called teprotumumab N01 works better than standard steroid treatment for controlling active Thyroid Eye Disease. About 92 adults with moderate-to-severe, recently active disease will be randomly assigned to receive either the new drug or the standard intravenous steroids. Researchers will mainly measure how much the bulging of the eye improves and check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, 200125, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.